Rosuvastatin + ezetimibe + bempedoic acid

Rosuvastatin + ezetimibe + bempedoic acid has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Oct 26, 2026: “LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy”.

1 paper studies itUpdated Oct 26, 2026

PubChem PubChem PubChem ChEBI ChEBI ChEBI

1 new paper in 30 daysSee all 1

Humans1

Latest

1 paper in 12 months

ESC Congress 2026 AbstractOct 26

LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy

Cohort study of 426 peopleInterventions